Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CCKAR | P32238 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657006 | 0.83 | ALDH1A1 (0.44) | MAPTTP53MEN1KMT2A | |
| SCHEMBL656755 | 0.76 | MAPT (0.42) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL12521109 | 0.74 | IRAK4 (0.39) | MAPTLMNATP53 | |
| SCHEMBL16104251 | 0.71 | IRAK4 (0.42) | CYP3A4 | |
| SCHEMBL659011 | 0.71 | AKR1C3 (0.36) | MAPTLMNAMEN1KMT2AMAPK1 | |
| SCHEMBL14362730 | 0.71 | HTR3E (0.63) | MAPTLMNAGFERMEN1KMT2A | |
| SCHEMBL657660 | 0.69 | IRAK4 (0.38) | MAPT | |
| SCHEMBL658508 | 0.68 | DRD2 (0.44) | MAPTLMNAMEN1KMT2ACYP3A4 | |
| SCHEMBL660056 | 0.67 | MAPT (0.38) | MAPTLMNATP53MEN1KMT2A | |
| SCHEMBL658996 | 0.67 | TP53 (0.36) | MAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-2406243-B1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2406243-A1 | BENZOFURAN DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| WO-2010104194-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | MAPT 3969/4885LMNA 3793/4885GFER 1399/4885 |
| US-20100234357-A1 | Benzofuran derivatives | AHR, BRPF3, CBR3 | MAPT 3969/4885LMNA 3793/4885GFER 1399/4885 |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | MAPT 3969/4885LMNA 3793/4885GFER 1399/4885 |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | BRPF3, BRD1, CBR3 | MAPT 4353/4885LMNA 3390/4885GFER 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.